JMJD2A predicts prognosis and regulates cell growth in human gastric cancer

Hu, Cheng‐En; Liu, Yong-Chao; Zhang, Huidong; Huang, Guangjian

doi:10.1016/j.bbrc.2014.04.126

Cited by 39 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, SIRT2 has been found to be downregulated in a variety of carcinomas and exhibits tumorsuppressive activity ( Hiratsuka et al, 2003 ;Peck et al, 2010 ;Kim et al, 2011 ;Li et al, 2013a ;Lee et al, 2014 ), while JMJD2A was demonstrated as an oncogene and up-regulated in carcinomas ( Kauffman et al, 2011 ;Berry et al, 2012 ;Kogure et al, 2013 ;Hu et al, 2014 ). We further studied that biological function of SIRT2 and JMJD2A in NSCLC cells.…”

Section: Discussionmentioning

confidence: 94%

“…JMJD2A, a lysine trimethyl-specific histone demethylase, was reported to be high expressed in a variety of carcinomas ( Kauffman et al, 2011 ;Berry et al, 2012 ;Kogure et al, 2013 ;Hu et al, 2014 ), reflecting the oncogenic potential. It was found that JMJD2A was over-expressed in mouse and human lung cancers.…”

Section: Discussionmentioning

confidence: 99%

“…Previous evidences showed that JMJD2A is overexpressed in a variety of carcinomas, including lung cancer, gastric cancer, bladder cancer, breast cancer, etc. ( Kauffman et al, 2011 ;Berry et al, 2012 ;Kogure et al, 2013 ;Hu et al, 2014 ). Excessive expression of JMJD2A interferes with the balance between methylation and demethylation, and affects the construction of heterochromatin.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A

Jiang

Shen

et al. 2015

Biological Chemistry

View full text Add to dashboard Cite

Lung cancer has been the most prolific cancer in China - as in the rest of the world - with a high death rate and low 5-year survival rate. Previous evidence showed that JMJD2A is over-expressed in human non-small cell lung cancer (NSCLC) tissues compared to adjacent normal tissues, and that high level of JMJD2A predicts poor overall and disease-free survival. However, the mechanism by which JMJD2A is regulated in human NSCLC is not fully understood. In the present study, we identified that the SIRT2 as an anti-oncogenic protein in NSCLC was down-regulated. JMJD2A as a target of SIRT2 was negatively correlated with SIRT2 level in NSCLC. SIRT2 bound to the promoter region of JMJD2A and negatively regulated JMJD2A expression. In addition, we found that SIRT2 inhibited NSCLC cells proliferation, colony formation and tumor growth in vitro and in vivo in a JMJD2A-dependent manner. In summary, our findings implicate that SIRT2 suppresses non-small cell lung cancer growth through targeting JMJD2A and SIRT2 activator may serve as candidate drug for NSCLC therapy.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A

Jiang

Shen

et al. 2015

Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Oncogenetic features of JMJD2A have been widely reported in breast cancer [12], colon cancer [13], gastric cancer [14], bladder cancer [15], and so on. The role of JMJD2A in cancer cellular proliferation is also verified via JMJD2A silencing in osteosarcoma cells [16].…”

Section: Introductionmentioning

confidence: 99%

Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma

Dong

2015

Med Oncol

View full text Add to dashboard Cite

JMJD2B and JMJD2C, histone demethylases, play crucial roles in cancer development and are up-regulated in many cancers. However, the actions of JMJD2B and JMJD2C in osteosarcoma remain unknown. The levels of JMJD2B or JMJD2C were evaluated in osteosarcoma cells and tissues via quantitative real-time PCR and Western Blot. JMJD2B and JMJD2C were up-regulated in osteosarcoma tissues when compared to paired adjacent non-tumor tissues. A higher level of JMJD2B or JMJD2C was related with metastasis of osteosarcoma cells. Fibroblast growth factor 2 (FGF2) is an important factor to maintain immaturity of cells and contributes to osteosarcoma aggressiveness. Elevated levels of FGF2 promoted the proliferation, migration, and invasion of osteosarcoma cell, while FGF2 was up-regulated by JMJD2B or JMJD2C. GST pull-down assay showed that JMJD2B or JMJD2C interacted with FGF2. Thus, JMJD2B and JMJD2C play an important role in the pathology of osteosarcoma via the up-regulation of FGF2. JMJD2B and JMJD2C should be developed potential targets for the therapy of osteosarcoma patients.

show abstract

“…The depletion of this protein induces apoptosis of gastric cancer cells by upregulating the expression of pro-apoptotic proteins and microRNA (miR-34a) and by downregulating anti-apoptotic proteins. Importantly, KDM4A expression is associated with tumor stage and nodal status, and high levels of this protein predict poor overall and disease-free survival [131].…”

Section: The Kdm4 Cluster (Jmjd2 Subfamily)mentioning

confidence: 99%

Lysine-Specific Histone Demethylases Contribute to Cellular Differentiation and Carcinogenesis

Verde

Querol-Paños²,

Cebrià-Costa³

et al. 2017

Epigenomes

View full text Add to dashboard Cite

Histone modifications regulate chromatin structure, gene transcription, and other nuclear processes. Among the histone modifications, methylation has been considered to be a stable, irreversible process due to the slow turnover of methyl groups in chromatin. However, the discovery of three different classes of lysine-specific demethylases-KDM1, Jumonji domain-containing demethylases, and lysyl oxidase-like 2 protein-has drastically changed this view, suggesting a role for dynamic histone methylation in different biological process. In this review, we describe the different mechanisms that these enzymes use to remove lysine histone methylation and discuss their role during physiological (cell differentiation) and pathological (carcinogenesis) processes.

show abstract

JMJD2A predicts prognosis and regulates cell growth in human gastric cancer

Cited by 39 publications

References 21 publications

SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A

SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A

Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma

Lysine-Specific Histone Demethylases Contribute to Cellular Differentiation and Carcinogenesis

Contact Info

Product

Resources

About